@comeonin - I have no enemies except the people who put profits before integrity and only invest to make money without regard for humanity. You cite Bangladesh as an example of poor starving workers just as a factory building collapses killing hundreds there. Did your investments make you some money?
Once again Mr. Alexandre has intelligently responded to the protestations of Mr. Yu & Mr. Liu who appear to be championing the PRC, by presenting facts from China sources. I also believe the American goose will not be so reliant on imports from China in the future, as we must reinvigorate our manufacturing base and then buy American made consumer goods. One need not visit a country to understand why you wouldn't want to be there or invest there!
To Comeonin: What happens when 1 billion people find that everything they have been working for is a lie, that all govt words mean nothing, that they will never become part of the new 300 million "middle class" Chinese, and that all the apartment buildings waiting for buyers and renters will never be lived in...revolution! I am not short the Chinese market and have not invested in Chinese real estate as you may have, but am long US equities & fixed and enjoying retirement thanks very much!
Wow, great article by Alexandre and excellent comments as well to back up his projections. Am inclined to buy the story of a financial disaster waiting to happen in China. As the corruption by party officials is uncovered and a middle class emerges in China, the collapse of real estate investments and lenders institutions due to a credit bubble just may produce a true revolution by the people. The recovery seen in democratic countries from similar recessions may not be possible in a totalitarian system. Cannot wait to see what happens.
While Pfizer (PFE +1.2%) has spun off its animal-health unit and sold its infant-nutrition business over the past year, it "absolutely" plans to keep its $3.2B/year consumer-health ops, CEO Ian Read has told investors. Read reckons that the unit is critical for Pfizer to take advantage of a growing trend in which prescription drugs gain over-the-counter status. [View news story]
I completely agree with Sejd213's comments re. CEO Ian Read and don't forget the selling of the Nutrition business for $11+ billion in order to continue to focus on the core discovery & development of new drugs for PFE. Also there is a small segment of "investors" commenting on PFE articles that say the wyeth acquisition was a big mistake yet this brought Pfizer Enbrel, Premarin, Pristiq and Prevnar the #1 vaccine in the world! The stock will continue to increase in value to $34-37 by end of 2014 and pay nice dividends for smart investors.
Pfizer's Next Big Deal Will Generate Income For Novartis, Prevent Competitors' Initiative [View article]
Hey jimmy46, from looking at your photo u r the old bugger and so when u come down with cancer or diabetes or an infection I am sure u will refuse all meds from those corrupt pharma co's that fake trials! I started my career as a pharma sales rep and retired 41 yrs later as an Executive Board member so I know the good my industry has done in this world and feel very sorry for people who can only cry in desperation at how life is unfair and corporations have screwed the little guy. The truth is life passed u by while u were tilting at wind mills, and I feel u are unhappy and can only complain about all the reasons why you failed to become successful.
Pfizer's Next Big Deal Will Generate Income For Novartis, Prevent Competitors' Initiative [View article]
Well Jimmy46 u can point out all of the unfairness in the universe as u and your minions see it but while u are bloviating I have made 1000's upon 1000's of $ by investing in Pfizer over past 25 years and am now very comfortably retired and dividends provide a cash flow placing me in top 2 %. Keep up the chatter but know that drugs from pharma n PFE have saved n prolonged more human lives than any blogger trying to save mankind from the wrongs of society.
Pfizer: 2012 Review And 2013 Outlook [View article]
Actually the patent on etanercept (Enbrel) expired in Nov 2012, so as FDA regulations on biogenerics or biosimilars become clear, cheaper competitors will begin to appear in the US market, and are already on the market in China & South America.
Pfizer: 2012 Review And 2013 Outlook [View article]
Good report which highlights the reasons I remain long in PFE and count on a continuing dividend flow thru 2013 and beyond. One additional comment is that there is tremendous upside to the newly approved Tofacitinib drug beyond rheumatoid arthritis, as it has performed very well in clinical trials of other autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and additional indications are being evaluated for possible development. stay tuned to this pharma for the future...
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
Have owned MO for more than 30 years and am very comfortably retired thanks in part to this investment. Every time its demise was predicted I added to my position, so I always welcomed the naysayers, lawyers, advisers and pundits pointing to all the reasons why one should not buy the stock.
Apple's Falling Share Price And The Market's Implicit Growth Implications [View article]
Lots of commentary on Apple which is very entertaining but for my money, "gathurm" made the most sense out of all the noise because at the end of the day, it's all about the marketplace in which you compete and how you compare to your competition. Nobody has been able to beat Apple at the game of innovation in electronics as yet, and until that happens, it's a good investment. It's a simple model called Marketing 101.
Pfizer's (PFE) anti-smoking drug Chantix produced a higher rate of heart attacks or strokes in patients using the treatment than those who didn’t, the FDA said today in a safety notice on its website. According to an analysis of clinical trials, the number of cardiovascular issues in patients on Chantix and those who took a placebo was uncommon. While the increased risk wasn’t statistically significant for those on Chantix, the FDA thinks it's “more likely that it is related to the drug and not purely a chance finding.” [View news story]
This is typical FDA cover your a_s mentality since they have missed so many other possibly harmful outcomes on new drugs, but the most important message was the following: " It is important to note that smoking is a major risk factor for cardiovascular disease, and Chantix is effective in helping patients to quit smoking and abstain from it for as long as one year. The health benefits of quitting smoking are immediate and substantial." We are all going to die one day, smokers sooner rather than later!
Darden Restaurants Vs. McDonald's: Which Is The Better Investment? [View article]
Whew, that was a close call between Darden & McDonalds but one I am happy about since I added MCD to my portfolio last month! Good analysis by Mr Alfonso.
A very nice well balanced article on PFE from Horizon Investments which points out very accurately the pros & cons of investing in this company. I am long PFE and do believe the future will be profitable for PFE shareholders but as described in this review, there are no slam dunks and if it were easy to pick the winners, we would all be rich.
China's 15 Minutes Of Fame Are Up [View article]
China's 15 Minutes Of Fame Are Up [View article]
China's 15 Minutes Of Fame Are Up [View article]
I am not short the Chinese market and have not invested in Chinese real estate as you may have, but am long US equities & fixed and enjoying retirement thanks very much!
China's 15 Minutes Of Fame Are Up [View article]
While Pfizer (PFE +1.2%) has spun off its animal-health unit and sold its infant-nutrition business over the past year, it "absolutely" plans to keep its $3.2B/year consumer-health ops, CEO Ian Read has told investors. Read reckons that the unit is critical for Pfizer to take advantage of a growing trend in which prescription drugs gain over-the-counter status. [View news story]
Pfizer's Next Big Deal Will Generate Income For Novartis, Prevent Competitors' Initiative [View article]
Pfizer's Next Big Deal Will Generate Income For Novartis, Prevent Competitors' Initiative [View article]
Pfizer: 2012 Review And 2013 Outlook [View article]
Pfizer: 2012 Review And 2013 Outlook [View article]
Apple: 2013 Will Be Rewarding To Shareholders [View article]
Altria (MO) declares $0.44/share quarterly dividend, in line with previous. Forward yield 5.29%. For shareholders of record Dec. 26. Payable Jan. 10. Ex-div date Dec. 21. (PR) [View news story]
Apple's Falling Share Price And The Market's Implicit Growth Implications [View article]
Pfizer's (PFE) anti-smoking drug Chantix produced a higher rate of heart attacks or strokes in patients using the treatment than those who didn’t, the FDA said today in a safety notice on its website. According to an analysis of clinical trials, the number of cardiovascular issues in patients on Chantix and those who took a placebo was uncommon. While the increased risk wasn’t statistically significant for those on Chantix, the FDA thinks it's “more likely that it is related to the drug and not purely a chance finding.” [View news story]
We are all going to die one day, smokers sooner rather than later!
Darden Restaurants Vs. McDonald's: Which Is The Better Investment? [View article]
Pfizer's Pipeline Offers Diversified Product Portfolio [View article]